CognitiveInvestigational

Cerebrolysin

Intravenous, Intramuscular injection

Overview

A porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids that mimic the action of endogenous neurotrophic factors. Cerebrolysin exhibits neurotrophic activity similar to BDNF, GDNF, and CNTF, promoting neuronal survival, synaptic plasticity, and neurogenesis.

Mechanism of Action

It modulates GSK-3beta, CDK5, and calcineurin-NFAT signaling cascades involved in neurodegeneration..

Research Summary & Key Findings

Approved in over 50 countries (not FDA-approved) for stroke, traumatic brain injury, and Alzheimer's disease. A meta-analysis of clinical trials showed modest improvements in global clinical function in Alzheimer's patients (Gauthier et al., Dement Geriatr Cogn Disord, 2015). The CASTA trial in acute ischemic stroke showed improved outcomes at 90 days. Safety concerns regarding prion transmission from porcine brain tissue have been raised but not substantiated.

Clinical Status

Investigational

Cerebrolysin is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

IntravenousIntramuscular injection

Related Peptides in Cognitive

Find a Provider

Find a verified provider who offers Cerebrolysin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Cerebrolysin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.